Atlas market file · Equity · United States
AbbVie Inc.ABBV
- Last close
- 243.87
- Change
- -0.95%
- 96-bar range
- 190.75 – 267.47
- As of
- 6 Aug 2026
AbbVie Inc. is a pharmaceutical preparations issuer listed as ABBV on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ABBV
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+23.45% over the window).
Source rail: Yahoo Finance chart API (ABBV). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ABBV. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
ABBV Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
ABBV public profile
Pharmaceutical preparations issuer. AbbVie Inc. is connected to current market context, cited company sources and its retained research file.
AbbVie Inc. trades as ABBV on NYSE. AbbVie Inc. (ABBV) has a latest verified close of 243.87, down 0.95%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ABBV under USA Stocks for browsing.
What changed for AbbVie Inc. today
AbbVie Inc. (ABBV) reported Q1 2026 revenue of $15B and net income of $695M, but its balance sheet remains a financial puzzle: $136.46B in assets vs. negative $6.66B equity, a gap wider than a pharmaceutical sales rep’s expense account. The company’s immunology division treats over 1M patients globally across 175 countries, yet its cash reserves ($9.39B) barely cover three months of operating expenses ($3.83B in Q1 cash flow).
On June 22, AbbVie announced a ‘strategically complementary’ merger with Apogee Therapeutics, touting future EPS accretion starting in 2032-a timeline so distant it makes pension fund investing look impatient. Meanwhile, insider selling hit $5.5M in early July, with executives offloading shares while the company’s buyback program remains conspicuously silent in recent filings.
Inventory levels ballooned to $5.05B (up $184M quarter-over-quarter), raising questions about demand forecasting for Humira alternatives or potential supply chain hiccups. With a 10-YEAR wait for the Apogee deal to pay off, shareholders might want to check if AbbVie’s ‘long-term growth’ story comes with a money-back guarantee. (source: SEC EDGAR filings, https://www.sec.gov/edgar/browse/?CIK=1551152)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ABBV technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ABBV
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ABBV research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ABBV FAQ
What is AbbVie Inc. (ABBV)?AbbVie Inc. (ABBV) has a latest verified close of 243.87, down 0.95%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
AbbVie Inc. (ABBV) has a latest verified close of 243.87, down 0.95%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ABBV?AbbVie Inc. (ABBV) has a latest verified close of 243.87, down 0.95%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
AbbVie Inc. (ABBV) has a latest verified close of 243.87, down 0.95%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ABBV under USA Stocks for browsing.
How often is the ABBV page updated?The ABBV public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ABBV public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ABBV?The ABBV file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:ABBV. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The ABBV file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:ABBV. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ABBV?Yes. The workstation can open ABBV, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ABBV, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ABBV page investment advice?No. The ABBV page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ABBV page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →